BridgeMD
New treatment option for CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Official title Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)
ClinicalTrials.gov ID: NCT04589299
What this study is testing
What is Immunoglobulin?
Immunoglobulin is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for cidp - chronic inflammatory demyelinating polyneuropathy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- SIDEC - (Subcutaneous Immunoglobulin in De-novo CIDP) ia a study designed as a randomized, parallel study with an open-label extension phase. The aims are to compare the effect of SCIG and IVIG in 60 treatment-naïve CIDP patients, and to detect the lowest effective dosage for maintenance treatment.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Fulfilling EFNS/PNS criteria for definite, probable or pure motor CIDP.
- No previous treatment with IVIG or SCIG.
- Age ≥ 18.
- ODSS ≥ 2 - either (arm/leg): 1/1, 2/0 or 0/2 at the time of inclusion. Clinical criteria for typical CIDP
- Chronically progressive, stepwise, or recurrent symmetric proximal and distal weakness and sensory dysfunction of all extremities, developing over at...
You likely can't join if
- Other causes of neuropathy
- Increased risk of thromboembolism
- Pregnancy (Plasma HCG is tested at inclusion in all fertile women)
- Breast feeding
- Malignancy
- Severe medical disease
See the full eligibility criteria
- Fulfilling EFNS/PNS criteria for definite, probable or pure motor CIDP.
- No previous treatment with IVIG or SCIG.
- Age ≥ 18.
- ODSS ≥ 2 - either (arm/leg): 1/1, 2/0 or 0/2 at the time of inclusion. Clinical criteria for typical CIDP
- Chronically progressive, stepwise, or recurrent symmetric proximal and distal weakness and sensory dysfunction of all extremities, developing over at least 2 months; cranial nerves may be affected.
- Absent or reduced tendon reflexes in all extremities. Criteria for pure motor CIDP Pure motor affection; otherwise as for typical CIDP. Electrophysiological criteria for CIDP
- Motor distal latency prolongation ≥50% above ULN in two nerves (excluding median neuropathy at the wrist from carpal tunnel syndrome), or
- Reduction of motor conduction velocity ≥30% below LLN in two nerves, or
- Prolongation of F-wave latency ≥30% above ULN in two nerves (≥50% if amplitude of distal negative peak CMAP ≤80% of LLN values), or
- Absence of F-waves in two nerves of these nerves have distal negative peak CMAP amplitudes ≥20% of LLN + ≥1 other demyelinating parameter in ≥1 other nerve, or
- Partial motor conduction block: ≥50% amplitude reduction of the proximal negative peak CMAP relative to distal, if distal negative peak CMAP \>20% of LLN, in two nerves, or in one nerve + ≥1 other demyelinating...
- Abnormal dispersion (≥30% duration increase between the proximal and distal negative peak CMAP) in ≥2 nerves, or
- Distal CMAP duration (interval between onset of the first negative peak an return to baseline of the last negative peak) increase in ≥1 nerve (median ≥6.6 ms, ulnar ≥6.7 ms, peroneal ≥7.6 ms, tibial ≥8.8 ms) + ≥1 other...
- Other causes of neuropathy
- Increased risk of thromboembolism
- Pregnancy (Plasma HCG is tested at inclusion in all fertile women)
- Breast feeding
- Malignancy
- Severe medical disease
- Other immune modulating treatment than low dose steroid (prednisolon \< 25 mg daily) within the last 6 months prior to inclusion
- Hepatitis B or C or HIV infection (screening at inclusion)
- Known IgA deficiency
- Known allergy to consents in PRIVIGEN or HIZENTRA
- Body weight \> 120 kg After treatment initiation:
- Pregnancy
- Serious medical disease that affects treatment or examinations
- Non-compliance to treatment
- Initiation of other immune modulating therapy
- Unacceptable side effects
- Withdrawal of consent to participate (drop-out)
The study team makes the final eligibility decision.
Where it's taking place
- Aalborg, Denmark
- Aarhus C, Denmark
- Copenhagen, Denmark
- Odense, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aalborg, Denmark; Aarhus C, Denmark; Copenhagen, Denmark; Odense, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.